Stage IIIA Breast Cancer Completed Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0028774 (Stage IIIA Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01959490Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast CancerBasic Science
NCT00194779Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By SurgeryTreatment
NCT00407888Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With SurgeryTreatment
NCT00119262Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerTreatment
NCT00378313A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast CancerTreatment
NCT01688609Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast CancerTreatment